Sort   by:  
 Page size 
UnknownN-(Pyrazin-2-yl)-1,8-naphthyridin-2-amine.
Not available
S-EPMC3588492 | biostudies-literature
UnknownSafety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trial.
Not available
S-EPMC8127508 | biostudies-literature
UnknownEffect of Argatroban Plus Intravenous Alteplase vs Intravenous Alteplase Alone on Neurologic Function in Patients With Acute Ischemic Stroke: The ARAIS Randomized Clinical Trial.
Not available
S-EPMC9912168 | biostudies-literature
UnknownTransarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001).
Not available
S-EPMC9905571 | biostudies-literature
UnknownImmune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.
Not available
S-EPMC11090892 | biostudies-literature
UnknownGuidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
Not available
S-EPMC4835977 | biostudies-literature
UnknownProspects for observing and localizing gravitational-wave transients with Advanced LIGO, Advanced Virgo and KAGRA.
Not available
S-EPMC5920066 | biostudies-literature
UnknownGlobal burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
Not available
S-EPMC11120204 | biostudies-literature
UnknownBurden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
Not available
S-EPMC12535840 | biostudies-literature
Sort   by:  
 Page size